Abstract. Breast cancer (BC) is the most common malignant tumor among women worldwide. Development of novel molecular targets is important to improve prognosis of BC patients. Derlin 3 (DERL3) gene is a member of derlin family, and its coding protein is critical to the endoplasmic reticulumassociated degradation mechanism. However, its oncological role in breast cancer remains unclear. This study evaluated DERL3 expression and function in BC. We analyzed DERL3 mRNA in 13 BC and two non-cancerous cell lines, and explored effects of DERL3 knockdown on BC proliferation, invasion and migration. We also evaluated correlation of DERL3 mRNA expression levels with clinicopathological factors and prognosis in 167 BC patients. DERL3 mRNA expression was detected in five (38%) BC cell lines. Inhibiting DERL3 expression significantly decreased proliferation and invasion in BC cells. Specimens from patients with lymph node metastasis had higher DERL3 mRNA expression than those without (P=0.030). Patients in the highest quartile for DERL3 mRNA expression (n=42) were more likely to experience shorter overall survival than other patients (P=0.032). These findings indicate that DERL3 promotes malignant phenotype in BC cells. DERL3 may serve as a potential prognostic marker and therapeutic target for BC.
Introduction
Breast cancer (BC) is the most common malignant tumor and the highest cause of cancer-related deaths in women world-wide (1) . Because of the development of adjuvant medication therapy such as chemotherapy, endocrine therapy and anti-human epidermal growth factor 2 (HER2) therapy, prognosis of BC patients has improved (2). The 5-, 10-and 15-year relative survival rates are 89, 83 and 78%, respectively (3). However, recurrent BC after resection is still difficult to cure (4) . Therefore, development of novel molecular targets is still required. Several commercial multigene expression assays are available (5) . Although they can help evaluate prognosis and appropriateness of adjuvant chemotherapy, additional informative biomarkers may improve their accuracy.
Derlin3 (DERL3) gene is located at 22q11.23; its protein locates in the endoplasmic reticulum (EnRt). It belongs to the Derlin family (DERL1, DERL2 and DERL3), which mediates endoplasmic reticulum-associated degradation (ERAD) of misfolded proteins, one of the EnRt stress responses (6) (7) (8) (9) . Reportedly, EnRt stress responses contribute to cancer progression (10, 11) . Although DERL1 overexpression is reported in BC (12) , colon cancer (13) and non-small cell lung cancer (NSCLC) (14) , no studies have addressed the role of DERL3 in BC. Referring to EnRt stress responses in BC, previous studies demonstrate that GRP78, an EnRt chaperone (15) , is overexpressed in high-grade BC (16) and XBP-1, a UPR-related transcription factor, is overexpressed in BC (17) . The relationship between DERL3 and these molecules remains elusive.
In searching for a new therapeutic target that is overexpressed in BC, we chose DERL3 as a candidate. This study therefore investigated DERL3 expression and functions to determine whether DERL3 is a potential biomarker and therapeutic target for BC. We obtained 13 human BC cell lines  (BT-20, BT-474, BT-549, HCC1419, HCC1954, Hs578T,  MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-415,  MDA-MB-468, SK-BR-3, 6 cells per each cell line), 167 primary BCs, and adjacent normal tissues using the RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. cDNA was synthesized from total RNAs (1 µg) by M-MLV Reverse transcriptase (Invitrogen, Frederick, Md, usa) and Primer 'random' (Sigma-Aldrich). The qRT-PCR of DERL3, GRP78 and XBP1 was performed using the SYBR Green PCR Core Reagents kit (applied Biosystems) as follows: 1 cycle of 95˚C (10 min); 40 cycles of 95˚C (5 sec), and 60˚C (60 sec). the primers specific for each gene were as follows: DERL3: forward 5'-CTCACTTTCCAGGCACCGT-3'and reverse 5'-TAGTAGATATGGCCCACCGC-3', which generated a 110-bp product; GRP78: forward 5'-GACATCAAGTTCTTG CCGTT-3' and reverse 5'-CTCATAACATTTAGGCCAGC-3' , which generated a 260-bp product (20); and XBP1: forward 5'-CAGACTACGTGCGCCTCTGC-3' and reverse 5'-CTTC TGGGTAGACCTCTGGG-3', which generated a 208-bp product (21) . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRna levels were quantified to normalize expression levels. Each sample was tested in triplicate; data are shown as (DERL3 value)/(GaPdh value) (22, 23) .
Materials and methods

Sample collection.
Inhibiting DERL3 expression by DERL3-specific small interfering RNAs (siRNAs).
Four kinds of siRNAs specific for DERL3 (siDERL3) were used to transfect BT-549 cells. Their sequences were siDERL3-1: 5'-GAUUCAGCUUCUUCU UCAATT-3'; siDERL3-2: 5'-UUGAAGAAGAAGCUGAAU CCCAGGGTT-3' (from a previous study) (24); siDERL3-3:
5'-UUGAAGUAGAGUUGAAAGGGG-3'; and siDERL3-4: 5'-UGAAGAAGAAGCUGAAUCCCA-3' (Hokkaido System Science, Sapporo, Japan). AccuTarget Negative Control siRNA Fluorescein-labeled (siControl; Cosmo Bio Co. Ltd., Tokyo, Japan) served as control nontargeting siRNA. The BC cells were seeded into 10-cm dishes with 10 ml of antibiotic-free RPMI-1640 with 10% FBs, and transfected with 400 pmol of siControl or siDERL3s in the presence of 40-µl LipoTrust EX Oligo (Hokkaido System Science) 24 h after seeding. After transfection, cells were cultured in antibiotic-free RPMI-1640 with 10% FBs for 72 h.
Western blotting. Cells were incubated in RIPa lysis buffer; lysates were stored at -30˚C. total protein lysates (20 µg/well) were electrophoretically transferred onto polyvinylidene difluoride membranes that were blocked using 5% skim milk in 0.05% PBs-t, and incubated at 4˚C overnight with rabbit anti-DERL3 polyclonal antibody (1:500; Abcam, Cambridge, UK). The membrane was then washed and probed with an anti-rabbit secondary antibody conjugated to horseradish peroxidase (Cell Signaling Technology, Beverly, MA, USA). β-actin served as endogenous control (25) .
Proliferation assay. Proliferation was evaluated using Cell Counting Kit-8 (CCK-8) (Dojindo Molecular Technologies, Inc., Kumamoto, japan). after transfection with siDERL3 (mixture of siDERL3-1, -2, -3 and -4), BT-549 cells (5x10 3 /well) were seeded into 96-well plates with RPMI-1640 containing 2% FBs. optical density of each well was measured 5 days after seeding, 2 h after adding 10 µl of CCK-8 solution.
Invasiveness assay. Invasiveness in Matrigel was determined using BioCoat Matrigel Invasion Chambers (Corning Inc., Corning, NY, USA) according to manufacturer's protocol. After transfection with mixed siDERL3s, BT-549 cells (2.5x10 4 /well) were suspended in serum-free RPMI-1640 and seeded in upper chambers. After 60 h of incubation, cells on membrane surfaces were fixed, stained, and counted in ten randomly selected microscope fields.
Migration assay. Migration of BT-549 cells was determined using a wound-healing assay. After transfection with mixed siDERL3s, BT-549 cells (3x10 4 /well) were seeded into each well of a 35-mm dish with culture insert (Ibidi, Martinsried, Germany) in RPMI-1640 containing 2% FBs. after 24 h, the insert was removed, and wound widths were measured at 100-µm intervals (20 measurements/well, x40 magnification) at cell-dependent time intervals.
Statistical analysis. Differences in DERL3 mRNA expression between two groups were evaluated using Mann-Whitney test. Correlations between DERL3 mRNA levels and those of GRP78 and XBP1 were analyzed using the Spearman's rank correlation test. significance of associations between DERL3 mRNA expression and clinicopathological parameters was analyzed with χ 2 test. Overall survival (OS) and disease-free survival (DFS) were calculated using Kaplan-Meier method; differences in survival curves were evaluated by log-rank tests. Multivariate regression analysis used Cox proportional hazards model to identify prognostic factors; variables for which P<0.05 were entered into the final model. all statistical analyses were performed on jMP 12 software (sas Institute Inc., Cary, nC, usa). P<0.05 was considered to indicate a statistically significant difference.
Results
DERL3 mRNA expression in BC and non-cancerous cell lines.
DERL3 mRna expression was detectable in five BC cell lines (38%), but not in other BC cell lines or non-cancerous cell lines (Fig. 1a) . In BC cell lines, DERL3 mRNA expression did not differ between estrogen receptor (ER) positive and ER negative, HER2 positive and HER2 negative, or triple-negative and other subtypes. ER and HER2 status of the cell lines were evaluated in previous studies (26, 27) . 
Expression analysis of DERL3 and genes encoding putative functional partners in BC cell lines.
We evaluated the correlation between DERL3 mRNA expression levels and the genes GRP78 and XBP1 that could potentially functionally interact with DERL3. There were no correlations between DERL3 and GRP78 mRna expression levels (correlation coefficient 0.253, P=0.405). Although it was not statistically significant, we found a weak correlation between DERL3 and XBP1 mRNA expression levels (correlation coefficient 0.335, P=0.263).
Effects of DERL3 inhibition on BC cell phenotypes. BT-549
cell line was transfected with siDERL3s to determine DERL3 functions in BC. western blot analysis confirmed that DERL3 was decreased by the transfections (Fig. 1B) . We evaluated proliferation, invasion, and migration. DERL3 inhibition significantly decreased proliferation over days 2-5 compared with the untransfected and siControl cells (P<0.001; Fig. 1C ). In the invasion assay, significantly fewer DERL3-inhibited cells invaded the Matrigel than did untransfected and siControl cells (P<0.001; Fig. 2a ). In contrast, there was no difference in the migration assay (Fig. 2B) . DERL3 mRna expression levels did not differ significantly between BC tissues and adjacent non-cancerous tissues (P=0.125). DERL3 mRNA expression levels were higher in BC tissues than in adjacent non-cancerous tissues for 94 (56.3%) of the 167 patients. Of note, DERL3 mRNA expression levels for several BC specimens were as low as their non-cancerous counterparts, whereas some BC specimens did express high DERL3 mRNA levels.
Clinical and prognostic significance of DERL3 mRNA expression in BC specimens. Among the 167 patients, we found DERL3 mRna expression to be significantly higher in those with lymph node (LN) metastasis (n=82) than in those without LN metastasis (n=85; P=0.030; Fig. 3A) . DERL3 expression did not differ with regard to t categories or uICC stage. among conventional biomarkers (Fig. 3B) , DERL3 mRNA expression in progesterone receptor (PgR)-negative specimens (n=52) was significantly higher than in PgR-positive specimens (n=115; P=0.019). There were not significant differences between ER-positive (n=127) and -negative (n=40; P=0.070), HER2-positive (n=39) and -negative (n=119; P=0.577; missing data for 9 patients), or triple-negative (n=18) and non-triple-negative specimens (n=148; P=0.467; missing data for 1 patient). We evaluated the correlation between DERL3 mRNA levels and XBP1 mRNA levels in the patients' BC specimens. There were no correlations between mRNA expression levels of these genes (correlation coefficient -0.011, P=0.884; Fig. 3C ).
The patients with the highest quartile of DERL3 expression were designated as 'high DERL3 group' (n=42), and the remaining patients were designated as 'others' (n=125). We found no significant differences with regard to any tested clinicopathological characteristics (table I) . the high DERL3 group experienced significantly shorter os than others (5-year OS, high DERL3 group: 87.9%; others: 94.3%; P=0.032; Fig. 4A ). Moreover, high DERL3 group tended to have poorer dFs than others, although there were no statistically significant differences (5-year DFS, high DERL3 group: 73.3%; others: 85.4%; P=0.114; Fig. 4B ).
Multivariate analysis of os identified uICC pathological stage III/IV disease (hR: 6.43; 95% CI: 2.26-20.3, P<0.001) as an independent prognostic factor, but not high DERL3 expression (hR: 2.27; 95% CI: 0.92-5.47, P=0.074; table II).
Discussion
In this study, we showed that DERL3 promotes BC cell proliferation and invasiveness, and that high DERL3 patients experienced poorer prognosis.
When cells undergo stress through hypoxia and nutrient deprivation, misfolded proteins increase, and activate the unfolded protein response (UPR) (11, 28) , which upregulates ERAD, and contributes to progression in cancer cells (10, 11) . Reportedly, GRP78, an EnRt chaperone (15) , is overexpressed in high-grade BC (16) . Furthermore, XBP-1, a UPR-related transcription factor, is overexpressed in BC, but is hardly detectable in non-cancerous breast tissues (17) . these findings suggest that UPR promotes a malignant BC phenotype. DERL1 is the most widely studied derlin (6), and regulated by the IRE-XBP1 pathway (8, 29) . Its overexpression reportedly prevents induction of apoptosis in stressed BC cells and correlates with advanced pathological tumor grade and node-positive status in BC (12) . It also contributes to malignant phenotype in colon cancer and in NSCLC by activating the PI3K/aKt and EGRF-EPK pathways, respectively (13, 14) .
There have been only a few studies on DERL3. Although DERL3 is assumed to be regulated by IRE1-XBP1 pathway such as DERL1 (8) , no significant correlations were found between DERL3 and XBP1 mRNA expression levels. There might be another pathway that regulates the expression of DERL3 in BC cells. According to previous studies, DERL3 has a protective function for cardiomyocytes through the ERAD mechanism (30), and low DERL3 expression has been associated with a more malignant phenotype and poorer prognosis in colorectal cancer (31) . We have shown that DERL3 mRNA is scarcely expressed not only in non-cancerous breast cell lines but also in several BC cell lines along with a considerable proportion of BC specimens. these findings suggest that both non-cancerous breast cells and BC cells express little DERL3 mRNA under slight EnRt stress.
DERL3 inhibition significantly decreased BC cell proliferation and invasion, and patients with high DERL3 group tended to be Ln metastasis-positive (P=0.054; table I). these results indicate that DERL3 does promote malignant phenotype when overexpressed in BC. Noteworthy, DERL1 mRNA overexpression also correlates with positive LN metastasis in BC, colon cancer and NSCLC by the inhibition of apoptosis and the activation of PI3K/aKt, EGRF-EPK pathways, respectively (12) (13) (14) . DERL3 might regulate such mechanisms in BC, and it promotes LN metastasis, leading to more malignant phenotype. Further studies are required to determine the underlying mechanisms. We found that the high DERL3 group experienced shorter OS, independently of ER, PgR and HER2 status, which implies its potential as a prognostic biomarker for all BC subtypes. these findings have several possible clinical applications. DERL3 levels in resected samples can help predict prognosis. Patients with high DERL3 specimens may require more aggressive adjuvant therapy; and if DERL3 mRNA expression levels can be determined from pre-surgical biopsies, they might help indicate whether neoadjuvant therapy is appropriate. Although further studies are warranted, our study suggests the possibility of developing new therapies for BC that target DERL3.
This study has some limitations. First, the roles of DERL3 in the ERAD pathway of cancer cells, and of ERAD in BC, are unclear. Pathway analyses might elucidate the role of DERL3 in UPR. Second, interventions such as adjuvant medication might have affected relationships between patient DERL3 mRNA levels and prognoses. Finally, these results were obtained from in vitro data and should be verified by in vivo studies.
In conclusion, we found DERL3 to promote a malignant BC phenotype. High DERL3 mRNA expression in the BC tissue resulted in poor prognosis. DERL3 mRNA expression is a potential prognostic marker and DERL3 protein could be a candidate therapeutic target for BC. 
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